Myelodysplastic Syndrome (MDS) Drugs Global Market Report 2025

Description

Myelodysplastic syndrome (MDS) drugs are pharmaceuticals utilized in the treatment of myelodysplastic syndrome, a group of bone marrow disorders characterized by insufficient production of healthy blood cells. These drugs operate by facilitating the restoration of normal gene function in bone marrow cells, leading to increased red blood cell production.

The primary categories of drugs used for myelodysplastic syndrome (MDS) treatment include chemotherapy and immunomodulatory drugs. Chemotherapy is a cancer treatment approach that employs anti-cancer medications to eliminate cancerous cells. These drugs can be administered via oral or parenteral routes to manage conditions such as refractory cytopenia with multilineage dysplasia, refractory anemia, and refractory anemia with ringed sideroblasts. Various healthcare settings, including hospitals, clinics, and ambulatory surgical centers, are involved in the distribution and administration of these drugs.

The myelodysplastic syndrome (MDS) drugs market research report is one of a series of new reports from The Business Research Company that provides myelodysplastic syndrome (MDS) drugs market statistics, including myelodysplastic syndrome (MDS) drugs industry global market size, regional shares, competitors with a myelodysplastic syndrome (MDS) drugs market share, detailed myelodysplastic syndrome (MDS) drugs market segments, market trends and opportunities and any further data you may need to thrive in the myelodysplastic syndrome (MDS) drugs industry. This myelodysplastic syndrome (MDS) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The myelodysplastic syndrome (MDS) drugs market size has grown strongly in recent years. It will grow from $3.47 billion in 2024 to $3.73 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to aging population, advancements in targeted therapies, clinical trials, increased awareness.

The myelodysplastic syndrome (MDS) drugs market size is expected to see strong growth in the next few years. It will grow to $5.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to genomic research, immunotherapies, global expansion of healthcare, biomarker identification. Major trends in the forecast period include personalized medicine, combinatorial therapies, symptom management, data sharing and collaboration.

The growing exposure to cancer treatments, such as chemotherapy and radiation, is expected to stimulate the expansion of the myelodysplastic syndrome (MDS) drug market in the coming years. Chemotherapy involves the use of medications to eliminate cancer cells, while radiation therapy employs high doses of radiation to target cancer cells and reduce tumor sizes. Both chemotherapy drugs and radiation treatments can negatively affect the bone marrow's stem cells, which play a crucial role in generating new blood cells. This disruption in normal cell production can lead to the development of MDS. Myelodysplastic syndrome (MDS) drugs offer various benefits in managing and treating MDS, a group of disorders characterized by abnormal blood cell production in the bone marrow. For instance, the European Society of Radiation Oncology (ESTRO) estimates that there will be a 16% increase in the number of radiotherapy treatment courses by 2025 based on projected cancer distributions. Consequently, the rising exposure to cancer treatments, including chemotherapy and radiation, is a driving force behind the growth of the myelodysplastic syndrome (MDS) drugs market.

The surge in myeloid leukemia cases is projected to advance the expansion of the myelodysplastic syndrome (MDS) drug treatment market. Myeloid leukemia is a type of cancer originating in the bone marrow, impacting the cells responsible for generating various blood cell types. Myelodysplastic syndrome (MDS) drugs aim to enhance bone marrow function by addressing the root causes of leukemia, thereby reducing the risk of complications associated with low blood cell counts, decreasing the necessity for chemotherapy and transplants, and ultimately improving survival rates for individuals with myelodysplastic syndrome (MDS). For example, the American Cancer Society estimates that there will be around 20,380 cases and 11,310 deaths in adults from acute myeloid leukemia (AML) in 2023. Consequently, the increasing incidence of myeloid leukemia is a key driver behind the myelodysplastic syndrome (MDS) drug market's growth.

Leading companies in the myelodysplastic syndrome (MDS) drugs market are concentrating on the development of new products, such as targeted therapies, to enhance patient outcomes, address specific customer needs, and integrate into the medical ecosystem. Targeted therapy for MDS involves drugs that precisely address genetic mutations or molecular irregularities in cancer cells, with the goal of improving outcomes by focusing on abnormal cells while reducing harm to healthy tissue. For example, in October 2023, the U.S. Food and Drug Administration (FDA) approved Tibsovo (ivosidenib) for treating adult patients with relapsed or refractory (R/R) MDS with an isocitrate dehydrogenase-1 (IDH1) mutation. This approval was based on the effectiveness of Tibsovo in an open-label, single-arm, multicenter study involving 18 adult patients with relapsed or refractory MDS with an IDH1 mutation.

In April 2022, GlaxoSmithKline plc, a focused biopharmaceutical company, acquired Sierra Oncology, Inc. for $1.9 billion. This acquisition supports GSK's broader strategy to strengthen its portfolio of specialty medicines and vaccines, with a focus on oncology and addressing unmet needs within the rare disease patient population. Sierra Oncology, Inc. is a U.S.-based biopharmaceutical company specializing in targeted therapies for treating rare cancers and myelodysplastic syndrome (MDS).

Major companies operating in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.

North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2024. The regions covered in myelodysplastic syndrome (MDS) drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the myelodysplastic syndrome (MDS) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myelodysplastic syndrome (MDS) drugs market consists of sales of vidaza (azacitidine), dacogen (decitabine) and reblozyl (luspatercept-aamt). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myelodysplastic Syndrome (MDS) Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myelodysplastic syndrome (mds) drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myelodysplastic syndrome (mds) drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myelodysplastic syndrome (mds) drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Type: Chemotherapy; Immunomodulatory Drugs
2) By Route Of Administration: Oral; Parenteral
3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia; Refractory Anemia; Refractory Anemia With Ringed Sideroblasts
4) By End User: Hospitals; Clinics; Ambulatory Surgical Centers
Subsegments:
1) By Chemotherapy: Hypomethylating Agents; Cytotoxic Agents
2) By Immunomodulatory Drugs: Lenalidomide; Thalidomide; Pomalidomide
Companies Mentioned: Bristol Myers Squibb; Otsuka Pharmaceutical Co. Ltd.; Teva Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Mylan NV
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r28574

1. Executive Summary

2. Myelodysplastic Syndrome (MDS) Drugs Market Characteristics

3. Myelodysplastic Syndrome (MDS) Drugs Market Trends And Strategies

4. Myelodysplastic Syndrome (MDS) Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Myelodysplastic Syndrome (MDS) Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Myelodysplastic Syndrome (MDS) Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Myelodysplastic Syndrome (MDS) Drugs Market Growth Rate Analysis
5.4. Global Myelodysplastic Syndrome (MDS) Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Myelodysplastic Syndrome (MDS) Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Myelodysplastic Syndrome (MDS) Drugs Total Addressable Market (TAM)

6. Myelodysplastic Syndrome (MDS) Drugs Market Segmentation

6.1. Global Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Immunomodulatory Drugs
6.2. Global Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
6.3. Global Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Refractory Cytopenia With Multilineage Dysplasia
Refractory Anemia
Refractory Anemia With Ringed Sideroblasts
6.4. Global Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Ambulatory Surgical Centers
6.5. Global Myelodysplastic Syndrome (MDS) Drugs Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hypomethylating Agents
Cytotoxic Agents
6.6. Global Myelodysplastic Syndrome (MDS) Drugs Market, Sub-Segmentation Of Immunomodulatory Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lenalidomide
Thalidomide
Pomalidomide

7. Myelodysplastic Syndrome (MDS) Drugs Market Regional And Country Analysis

7.1. Global Myelodysplastic Syndrome (MDS) Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Myelodysplastic Syndrome (MDS) Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market

8.1. Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Myelodysplastic Syndrome (MDS) Drugs Market

9.1. China Myelodysplastic Syndrome (MDS) Drugs Market Overview
9.2. China Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Myelodysplastic Syndrome (MDS) Drugs Market

10.1. India Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Myelodysplastic Syndrome (MDS) Drugs Market

11.1. Japan Myelodysplastic Syndrome (MDS) Drugs Market Overview
11.2. Japan Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Myelodysplastic Syndrome (MDS) Drugs Market

12.1. Australia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Myelodysplastic Syndrome (MDS) Drugs Market

13.1. Indonesia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Myelodysplastic Syndrome (MDS) Drugs Market

14.1. South Korea Myelodysplastic Syndrome (MDS) Drugs Market Overview
14.2. South Korea Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Myelodysplastic Syndrome (MDS) Drugs Market

15.1. Western Europe Myelodysplastic Syndrome (MDS) Drugs Market Overview
15.2. Western Europe Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Myelodysplastic Syndrome (MDS) Drugs Market

16.1. UK Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Myelodysplastic Syndrome (MDS) Drugs Market

17.1. Germany Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Myelodysplastic Syndrome (MDS) Drugs Market

18.1. France Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Myelodysplastic Syndrome (MDS) Drugs Market

19.1. Italy Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Myelodysplastic Syndrome (MDS) Drugs Market

20.1. Spain Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Myelodysplastic Syndrome (MDS) Drugs Market

21.1. Eastern Europe Myelodysplastic Syndrome (MDS) Drugs Market Overview
21.2. Eastern Europe Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Myelodysplastic Syndrome (MDS) Drugs Market

22.1. Russia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Myelodysplastic Syndrome (MDS) Drugs Market

23.1. North America Myelodysplastic Syndrome (MDS) Drugs Market Overview
23.2. North America Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Myelodysplastic Syndrome (MDS) Drugs Market

24.1. USA Myelodysplastic Syndrome (MDS) Drugs Market Overview
24.2. USA Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Myelodysplastic Syndrome (MDS) Drugs Market

25.1. Canada Myelodysplastic Syndrome (MDS) Drugs Market Overview
25.2. Canada Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Myelodysplastic Syndrome (MDS) Drugs Market

26.1. South America Myelodysplastic Syndrome (MDS) Drugs Market Overview
26.2. South America Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Myelodysplastic Syndrome (MDS) Drugs Market

27.1. Brazil Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Myelodysplastic Syndrome (MDS) Drugs Market

28.1. Middle East Myelodysplastic Syndrome (MDS) Drugs Market Overview
28.2. Middle East Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Myelodysplastic Syndrome (MDS) Drugs Market

29.1. Africa Myelodysplastic Syndrome (MDS) Drugs Market Overview
29.2. Africa Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Myelodysplastic Syndrome (MDS) Drugs Market Competitive Landscape And Company Profiles

30.1. Myelodysplastic Syndrome (MDS) Drugs Market Competitive Landscape
30.2. Myelodysplastic Syndrome (MDS) Drugs Market Company Profiles
- 30.2.1. Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Otsuka Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Mylan NV Overview, Products and Services, Strategy and Financial Analysis

31. Myelodysplastic Syndrome (MDS) Drugs Market Other Major And Innovative Companies

31.1. Cipla Limited
31.2. Acceleron Pharma Inc.
31.3. Aprea Therapeutics
31.4. Onconova Therapeutics Inc.
31.5. Geron Corporation
31.6. Amgen Inc.
31.7. Sandoz
31.8. Gilead Sciences Inc.
31.9. Johnson And Johnson
31.10. Lupin Ltd. Corporation
31.11. Ono Pharmaceutical Co. Ltd.
31.12. Eisai Co. Ltd.
31.13. Nippon Shinyaku Co. Ltd.
31.14. Lupin Ltd.
31.15. Accord Healthcare Inc.

32. Global Myelodysplastic Syndrome (MDS) Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Myelodysplastic Syndrome (MDS) Drugs Market

34. Recent Developments In The Myelodysplastic Syndrome (MDS) Drugs Market

35. Myelodysplastic Syndrome (MDS) Drugs Market High Potential Countries, Segments and Strategies

35.1 Myelodysplastic Syndrome (MDS) Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Myelodysplastic Syndrome (MDS) Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Myelodysplastic Syndrome (MDS) Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer